Elan and J&J, Sitting in a Tree ...

Elan (NYSE: ELN  ) is Johnson & Johnson's (NYSE: JNJ  ) new best buddy.

First J&J bought half of Elan's Alzheimer drug pipeline, and agreed to become Elan's partner on Tysabri if Biogen Idec (Nasdaq: BIIB  ) were ever acquired. Now Johnson & Johnson is kicking partner Alkermes (Nasdaq: ALKS  ) to the curb in favor of Elan's technology.

Yesterday, Alkermes said that J&J was discontinuing the development of a once-monthly version of its antipsychotic Risperdal. The company currently markets Risperdal Consta, developed using Alkermes' long-lasting technology, which allows the drug to be taken once every two weeks.

The development halt seems purely commercial in nature. As the patent expiration on Risperdal approached, Johnson & Johnson developed a follow-on drug called Invega, and then used Elan's NanoCrystal technology to develop a long-lasting version of the drug, called Invega Sustenna, which was approved by the Food and Drug Administration a few weeks ago.

Since Invega Sustenna is dosed once a month, sorry, Alkermes -- your services are no longer needed. Welcome to the party, Elan! Sit down and have a beer! We've got the U.S. market all to ourselves, at least until Eli Lilly (NYSE: LLY  ) finally clears up issues with its once-monthly Zyprexa.

Ironically, Eli Lilly is now Alkermes' ticket to getting out of the doghouse with investors. Eli Lilly and Amylin Pharmaceuticals (Nasdaq: AMLN  ) have a once-weekly version of their diabetes drug, Byetta, under review by the FDA, developed using -- you guessed it -- Alkermes' long-lasting technology.

Keep your chin up, Alkermes. You'll get a new friend soon enough.

Elan is a Motley Fool Rule Breakers pick. The newsletter is always on the hunt for hot drug stocks and other cutting-edge picks. Click here to see all of our latest discoveries with a free 30-day trial subscription.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Johnson & Johnson is a selection of the Income Investor newsletter. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (11)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 972998, ~/Articles/ArticleHandler.aspx, 7/29/2014 7:04:43 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement